La OMS decide detener temporalmente los estudios de la #hidroxicloroquina para tratar el #covid19 luego de que un estudio [el del Lancet] revelara que los pacientes tratados con ese medicamento tenían más posibilidades de muerte.
Bueno, yo creo que voy a cerrar el chiringuito hasta el próximo mes. A estos niveles de los índices paso de estar metiendo dinero y quiero ver esas velas semanales y mensuales a ver que me dicen antes de hacer nada mas . Había pensado en picotear algún que otro corto pero necesito recuperar capital mental así que me espero a revisión el fin de semana. +35% de rentabilidad en este primer semestre en operaciones cerradas. No es para tirar cohetes ni mucho menos dada la recuperación en V del mercado pero no he ampliado cash y he hecho lo que he podido con los dineros que me quedaban ( yo al casino voy al contado, nada de cfds) , tras tener la triple carga de AMRN inmovilizada ... que lamentablemente se llevaria todos los profits en caso de amputar , cosa que no voy hacer. Quedan otros 6 meses para finalizar el año y tomar una decisión al respecto. También tenemos unas elecciones de por medio, me temo, y el sector salud suele ser un target para reclutar ciertos votos. Desde luego no nos vamos aburrir, seguiremos con el pico y la pala como podamos. suerte con el ASCO :)
Colocación 250 millones de acciones (+15% ampliable).
it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $250,000,000 of its common stock. All of the shares are being offered by Arena. In addition, Arena intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
BofA Securities, Citigroup and SVB Leerink are acting as the joint book-running managers for the offering. Credit Suisse and Cantor are also acting as book-running managers for the offering. JMP Securities and Needham & Company are acting as co-managers for the offering.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
We are a biopharmaceutical company focused on delivering novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. Our internally-developed pipeline includes multiple potentially first- or best-in-class assets with broad clinical utility.
Our most advanced investigational clinical programs include:
| • | Etrasimod, which we are evaluating in a Phase 3 program for ulcerative colitis, or UC, a Phase 2b/3 program for Crohn’s disease, or CD, and a Phase 2b program in atopic dermatitis, or AD. We also plan to evaluate etrasimod in a Phase 2b program for eosinophilic esophagitis, or EoE, and a Phase 2 program in alopecia areata, or AA.
| • | Olorinab, which we are evaluating for a broad range of visceral pain conditions associated with gastrointestinal diseases and is currently in a Phase 2b trial for treatment of abdominal pain associated with irritable bowel syndrome, or IBS.
| • | APD418, which we are evaluating in a Phase 1 trial for acute heart failure, or AHF.
By 2028, we estimate the total annual market opportunity for etrasimod in AD will be approximately $23.9 billion, and that the total annual market opportunity for etrasimod across all indications in our current pipeline will be approximately $48.0 billion.
We continue to leverage our two decades of world-class G protein-coupled receptor, or GPCR, target discovery research to develop breakthrough drugs and ultimately deliver these to patients with large unmet needs. Our long-term pipeline prospects include an enhanced collaboration with Beacon Discovery across a broad range of immune-mediated inflammatory targets and compounds. We are also working on the buildout of our wholly owned subsidiary, Arena Neuroscience, Inc., which is expected to focus on programs and platforms in the area of neuroscience, including identifying and developing potential treatments for neurological conditions with microglial neuroinflammation. Initially, we anticipate that Arena Neuroscience will direct its activities towards the further evaluation and development of AN352, an early clinical stage compound that is expected to be evaluated for the treatment of rare epilepsies, as well as AN143 and AN659, preclinical stage compounds. To support its development activities, we may pursue third party investments in Arena Neuroscience.
We have license agreements or collaborations with various companies, including:
| • | United Therapeutics (ralinepag in a Phase 3 program for pulmonary arterial hypertension),
| • | Everest Medicines Limited (etrasimod in a Phase 3 program for UC in Greater China and select countries in Asia),
| • | Beacon Discovery (early research platform for GPCR targets), and
| • | Boehringer Ingelheim International GmbH (undisclosed orphan GPCR program for central nervous system – preclinical).
In April 2020, we announced positive topline data from a Phase 1 clinical study evaluating controlled-release delivery profiles, or CR, for our investigational agent, etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator. We plan to expand our current development program to rapidly develop etrasimod CR and integrate it into multiple, ongoing clinical development programs.
In May 2020, we announced that we completed enrollment of our Phase 2 ADVISE trial evaluating two dose levels etrasimod in development for the treatment of AD. ADVISE is a multicenter, randomized, double-blinded, placebo-controlled 16-week study (with a 52-week open-label extension) to assess the safety and efficacy of once-daily etrasimod in approximately 140 subjects with moderate-to-severe AD. We expect to announce topline data from this trial in the fourth quarter of 2020.
Also in May 2020, we announced the following program updates:
| • | our etrasimod ELEVATE UC 52 Phase 3 trial in UC is ongoing and on track; our ELEVATE UC 12 Phase 3 trial (which will be a randomized, double-blind, placebo-controlled, 12-Week study to assess the efficacy and safety of etrasimod in subjects with moderately to severely active UC) is expected to initiate in the second half of 2020; topline data for both trials is expected by the end of 2021;
| • | our etrasimod CULTIVATE Phase 2b dose-ranging trial in CD has been initiated and is ongoing; we are considering options to help facilitate availability of topline data in 2021; we are withdrawing previously announced overall program guidance based on expected COVID-19 impact on trial execution, including site activation and enrollment;
| • | our planning for a Phase 2b trial to evaluate etrasimod for the treatment of EoE and a Phase 2 trial to evaluate etrasimod for the treatment of AA is ongoing; we plan to initiate these trials in 2020, depending on the impact of COVID-19 in the third and fourth quarters of 2020;
| • | our olorinab CAPTIVATE Phase 2b trial in abdominal pain associated with IBS (IBS-C, IBS-D) is ongoing; we are experiencing some COVID-19 related impact on trial enrollment; topline data is expected in the fourth quarter of 2020 or first quarter of 2021; and
| • | our Phase 1 trial of APD418 for AHF is experiencing COVID-19 related impact with the trial temporarily paused; topline data is expected in the fourth quarter of 2020.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
